China-based drug developer Adagene raises $69m led by General Atlantic

China-based drug developer Adagene raises $69m led by General Atlantic

Adagene is a clinical stage oncology-based biotech company

China-headquartered drug developer Adagene has raised $69 million in a Series D funding round led by US global growth equity firm General Atlantic, per a company statement.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter